Assembly Biosciences (NASDAQ:ASMB) Sees Large Volume Increase – What’s Next?

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) saw strong trading volume on Wednesday . 364,071 shares traded hands during mid-day trading, an increase of 121% from the previous session’s volume of 164,453 shares.The stock last traded at $33.89 and had previously closed at $35.28.

Analyst Upgrades and Downgrades

ASMB has been the topic of a number of recent analyst reports. Zacks Research upgraded Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Mizuho set a $53.00 price objective on shares of Assembly Biosciences in a research report on Tuesday, September 1st. Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.60.

Assembly Biosciences Price Performance

The firm has a market capitalization of $673.42 million, a PE ratio of 32.44 and a beta of 1.13. The company’s fifty day simple moving average is $29.55 and its 200 day simple moving average is $28.31.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The company had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. On average, analysts anticipate that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of ASMB. Bank of America Corp DE increased its holdings in Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares during the period. California State Teachers Retirement System bought a new position in shares of Assembly Biosciences in the second quarter worth $103,000. Seven Fleet Capital Management LP purchased a new stake in shares of Assembly Biosciences in the fourth quarter worth $147,000. Acadian Asset Management LLC raised its position in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new stake in Assembly Biosciences during the fourth quarter valued at $228,000. 19.92% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.